This article is a narrative review that looks at current information about Metabolic Dysfunction-Associated Steatotic Liver Disease, known as MASLD. The authors gathered data from various sources to understand how common the condition is and how serious it can be. The review covers a global setting as well as specific data from China.
The analysis indicates that MASLD affects 38% of the population globally. In terms of severity, the review states that deaths worldwide from complications related to MASLD were approximately 134,000 in 2019. Furthermore, the data suggests that MASLD has become the leading cause of cirrhosis in China, having surpassed viral hepatitis in this regard.
Because this is a review rather than a study with a specific group of people followed over time, the results are based on reported numbers from different places. There were no safety concerns or adverse events reported in this review because it did not test a new treatment or intervention. Readers should take this information as evidence that MASLD is widespread and a major health concern, which can help guide future prevention and management strategies.